Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era - Archive ouverte HAL Access content directly
Journal Articles Cancer Treatment Reviews Year : 2017

Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era

(1) , (2, 3) , (1, 4)
1
2
3
4

Abstract

Leptomeningeal metastasis is a fatal manifestation seen in advanced cancer patients. Its incidence is increasing, reaching 3.8% in molecularly unselected non-small cell lung cancer patients and up to 5% and 9% in ALK-rearranged and EGFR-mutant lung cancer patients, respectively. The prognosis remains poor despite systemic treatment, intrathecal chemotherapy, radiation therapy and personalized treatments in molecularly selected patients. However, new therapies with improved cerebral-spinal fluid penetration have been developed for subgroups of molecular selected patients indicating they could be promising therapeutic options for managing leptomeningeal disease. Systemic chemotherapy, which may be combined with intrathecal chemotherapy, remains standard treatment for lung cancer patients with leptomeningeal disease and a good-risk profile. We summarize evidence reported in the literature for managing this complication in lung cancer patients. Based on this, we have selected potential therapeutic strategies that could be used in daily clinical practice.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02940527 , version 1 (16-09-2020)

Identifiers

Cite

J. Remon, E. Le Rhun, B. Besse. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer Treatment Reviews, 2017, 53, pp.128-137. ⟨10.1016/j.ctrv.2016.12.006⟩. ⟨inserm-02940527⟩
29 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More